Article
Oncology
Peter-Martin Bruch, Sascha Dietrich, Herve Finel, Ariane Boumendil, Hildegard Greinix, Thomas Heinicke, Wolfgang Bethge, Dietrich Beelen, Christoph Schmid, Hans Martin, Luca Castagna, Christof Scheid, Kerstin Schaefer-Eckart, Joerg Bittenbring, Juergen Finke, Henrik Sengeloev, Mael Heiblig, Jan Cornelissen, Patrice Chevallier, Mohamad Mohty, Stephen Robinson, Silvia Montoto, Peter Dreger
Summary: This retrospective study analyzed the outcomes of 162 adult patients with BPDCN who underwent a first HCT. The study found that MAC (especially TBI-based) significantly improved the prognosis of alloHCT recipients, and autoHCT could be considered for patients who are not eligible for MAC.
Article
Oncology
Yue Lu, Rui-Juan Sun, Jian-Ping Zhang, Fang Xu, Zhi-Cong Du, Ge-Le Tong, Yun Wang, Dao-Pei Lu
Summary: This study retrospectively analyzed the outcomes of 15 BPDCN patients who underwent allo-HSCT with myeloablative conditioning. The results showed that allo-HSCT with myeloablative conditioning is an effective option for BPDCN patients in complete remission, with most patients surviving after transplantation.
LEUKEMIA & LYMPHOMA
(2022)
Article
Oncology
C. Camero Yin, Naveen Pemmaraju, M. James You, Shaoying Li, Jie Xu, Wei Wang, Zhenya Tang, Omar Alswailmi, Kapil N. Bhalla, Muzaffar H. Qazilbash, Marina Konopleva, Joseph D. Khoury
Summary: Mutation and protein-level profiling have expanded our understanding of the pathogenesis of blastic plasmacytoid dendritic cell neoplasm (BPDCN), revealing a high prevalence of somatic mutations involving epigenetic regulators and RNA splicing factors, along with frequent mutations in genes such as ETV6 and IKZF1. Older age, multiple mutations, and mutations in the DNA methylation pathway are poor prognostic factors in BPDCN patients.
Review
Oncology
Hongyan Liao, Jiang Yu, Yu Liu, Sha Zhao, Huanling Zhu, Dongsheng Xu, Nenggang Jiang, Qin Zheng
Summary: This case demonstrates for the first time that prominent pDC proliferation can be associated with lymphoid neoplasms and can exhibit blastic morphology and immunophenotype. The underlying mechanism of the coexistence of these two blastic populations remains unknown.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Jinzhi Chen, Xi Zhang, Linlin Ma, Yuan Gao, Zhanli Fu, Meng Liu
Summary: This article reports a case of a BPDCN patient who developed PTLD after allogeneic HSCT. The case report suggests that PTLD should be considered when new enlarged lymph nodes occur in BPDCN patients, and F-18-FDG PET/CT can provide additional evidence for further diagnosis.
FRONTIERS IN MEDICINE
(2023)
Article
Pathology
Luisa Lorenzi, Silvia Lonardi, Donatella Vairo, Andrea Bernardelli, Michela Tomaselli, Mattia Bugatti, Sara Licini, Mariachiara Arisi, Lorenzo Cerroni, Alessandra Tucci, William Vermi, Silvia Clara Giliani, Fabio Facchetti
Summary: This study identifies EC as a novel pDC marker of diagnostic relevance in BPDCN. The results suggest a scenario where malignant pDCs promote the blunting of IFN-I signaling through EC-driven signaling, leading to a poorly immunogenic tumor microenvironment.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2021)
Review
Medicine, General & Internal
Hyo-jae Lee, Hye Mi Park, So Yeon Ki, Yoo-Duk Choi, Sook Jung Yun, Hyo Soon Lim
Summary: This case describes a rare presentation of BPDCN in the breast parenchyma, with no previous reports on the radiologic features of the disease within breast tissue. The patient was diagnosed using diagnostic breast imaging tools and underwent chemotherapy with peripheral blood stem cell transplantation, achieving complete remission.
Article
Medicine, Research & Experimental
Wei Cheng, Tian-tian Yu, Ai-ping Tang, Ken He Young, Li Yu
Summary: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy derived from plasmacytoid dendritic cells with unclear pathogenesis. Treatment is based on leukemia or lymphoma experience, relapse is quick with drug resistance.
CURRENT MEDICAL SCIENCE
(2021)
Article
Medicine, General & Internal
Li Zhang, Yidong Wang, Mingming Lu, Mengdan Shen, Zhao Duan
Summary: This study presents a case of a 37-year-old pregnant woman with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). It suggests that pregnant women diagnosed with BPDCN in the third trimester should promptly terminate the pregnancy for further treatment.
Article
Hematology
Corinn Small, Soham Mukerjee, Diwash Jangam, Sumanth Gollapudi, Kunwar Singh, David L. Jaye, Phyu P. Aung, Christiane Querfeld, Keluo Yao, Karen M. Chisholm, Sheeja Pullarkat, Sa Wang, Alejandro Gru, Mohammad Hussaini, Tracy I. George, Robert S. Ohgami
Summary: In this study, the exome sequence data of 9 BPDCN cases were analyzed. Results showed significant genetic changes related to tobacco exposure, aging, nucleotide excision repair deficiency, UV exposure, and endogenous deamination. These findings suggest that environmental and endogenous genetic changes may play a central role in the oncogenesis of BPDCN.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Article
Oncology
Lorenzo Canti, Stephanie Humblet-Baron, Isabelle Desombere, Julika Neumann, Pieter Pannus, Leo Heyndrickx, Aurelie Henry, Sophie Servais, Evelyne Willems, Gregory Ehx, Stanislas Goriely, Laurence Seidel, Johan Michiels, Betty Willems, Adrian Liston, Kevin K. Arien, Yves Beguin, Maria E. Goossens, Arnaud Marchant, Frederic Baron
Summary: Response to SARS-CoV-2 mRNA vaccination in allogeneic hematopoietic stem cell transplantation recipients is influenced by chronic GVHD and rituximab therapy. Immunological markers could assist in identifying allo-HCT patients at risk of poor antibody response to mRNA vaccination.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Medicine, General & Internal
Yemin Wang, Li Xiao, Lili Yin, Lv Zhou, Yanjuan Deng, Huan Deng
Summary: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic disease involving the skin and bone marrow. The immunophenotype of BPDCN is characterized by the expression of CD4, CD56, CD123, TCL-1, and CD303. Current treatment for BPDCN is based on high-dose chemotherapy combined with stem cell transplantation, but targeted therapies have shown great promise. This article focuses on the latest advances in genetics and targeted therapies for BPDCN, providing new ideas for its clinical treatment.
Article
Dermatology
Ying Zhang, Jingshu Xiong, Siqi Li, Yan Li, Xuebao Shao, Wei Zhang, Xiulian Xu, Yiqun Jiang, Jianfang Sun, Hao Chen
Summary: This retrospective study aims to characterize the clinical, histopathological, and immunophenotypic features of BPDCN with cutaneous involvement. The results showed that the morphological and phenotypic features of cutaneous BPDCN are heterogeneous. Notably, E2-2 may serve as a useful marker to definitively diagnose BPDCN.
EUROPEAN JOURNAL OF DERMATOLOGY
(2022)
Article
Pathology
Xin Zhang, Jing Han, Na Zhu, Yuan Ji, Yingyong Hou
Summary: This case report describes a rare case of systemic mastocytosis with aggressive involvement of the gastrointestinal tract. The patient exhibited symptoms of long-term abdominal discomfort and diarrhea, and was successfully treated with avapritinib, resulting in significant clinical improvement.
DIAGNOSTIC PATHOLOGY
(2023)
Letter
Oncology
Ruth-Miriam Koerber, Stefanie A. E. Held, Maria Vonnahme, Georg Feldmann, Joerg Wenzel, Ines Guetgemann, Peter Brossart, Annkristin Heine
Summary: Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an extremely rare disease with origins in dendritic cells, posing challenges in both diagnosis and treatment. It is difficult to distinguish from other leukemic conditions and lacks clear therapeutic standards.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Mohamed A. Kharfan-Dabaja, Ambuj Kumar, Facundo E. Stingo, Farhad Khimani, Mohammad Hussaini, Ernesto Ayala, Taiga Nishihori, Bijal Shah, Frederick L. Locke, Javier Pinilla-Ibarz, Julio C. Chavez
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2018)
Review
Oncology
Bhagirathbhai R. Dholaria, Ambuj Kumar, Abdel-Ghani Azzuqua, Taiga Nishihori, Mohamed A. Kharfan-Dabaja, Han W. Tun, Ernesto Ayala
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2019)
Article
Hematology
Erin A. Dean, Rahul S. Mhaskar, Hong Lu, Mina S. Mousa, Gabriel S. Krivenko, Aleksandr Lazaryan, Christina A. Bachmeier, Julio C. Chavez, Taiga Nishihori, Marco L. Davila, Farhad Khimani, Hien D. Liu, Javier Pinilla-Ibarz, Bijal D. Shah, Michael D. Jain, Yoganand Balagurunathan, Frederick L. Locke
Article
Biophysics
Elmariah Hany, Syeda Mahrukh Hussnain Naqvi, Jongphil Kim, Taiga Nishihori, Asmita Mishra, Lia Perez, Rawan Faramand, Aleksandr Lazaryan, Hien D. Liu, Farhad Khimani, Michael Nieder, Claudio Anasetti, Joseph Pidala, Nelli Bejanyan
Summary: Higher infused total nucleated cell dose in allogeneic bone marrow transplant with post-transplant cyclophosphamide is associated with improved overall survival. The study suggests that infused CD34+ cell doses >= 5 x 10(6) cells/kg may result in improved survival in patients receiving allogeneic PBSCT with PTCy. Targeting a CD34+ cell dose of >= 5 x 10(6) cells/kg for allogeneic PBSCT with PTCy is supported by these findings.
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Nelli Bejanyan, Joseph A. Pidala, Xuefeng Wang, Ram Thapa, Taiga Nishihori, Hany Elmariah, Aleksandr Lazaryan, Farhad Khimani, Marco L. Davila, Asmita Mishra, Rawan Faramand, Michael D. Jain, Leonel Ochoa, Lia Elena Perez, Hien Liu, Melissa Alsina, Mohamed A. Kharfan-Dabaja, Hugo Fernandez, Michael L. Nieder, Frederick L. Locke, Claudio Anasetti, Ernesto Ayala
Summary: The study demonstrates that GVHD prophylaxis with sirolimus/MMF following PTCy effectively prevents grade II-IV aGVHD after PB haplo-HCT, highlighting the need for a prospective comparison of sirolimus vs tacrolimus in combination with MMF for GVHD prophylaxis after PB HCT.
Article
Hematology
Reid W. Merryman, Robert A. Redd, Taiga Nishihori, Julio Chavez, Yago Nieto, Justin M. Darrah, Uttam Rao, Michael T. Byrne, David A. Bond, Kami J. Maddocks, Michael A. Spinner, Ranjana H. Advani, Hatcher J. Ballard, Jakub Svoboda, Anurag K. Singh, Joseph P. McGuirk, Dipenkumar Modi, Radhakrishnan Ramchandren, Jason Romancik, Jonathon B. Cohen, Matthew J. Frigault, Yi-Bin Chen, Anthony Serritella, Justine Kline, Stephen Ansell, Sunita Nathan, Maryam Rahimian, Robin M. Joyce, Mansi Shah, Kevin A. David, Steven Park, Anne W. Beaven, Alma Habib, Veronika Bachanova, Shazia Nakhoda, Nadia Khan, Ryan C. Lynch, Stephen D. Smith, Vincent T. Ho, Ann LaCasce, Philippe Armand, Alex F. Herrera
Summary: Autologous stem cell transplantation (ASCT) following anti-PD-1 therapy shows promising outcomes for relapsed/refractory Hodgkin lymphoma (HL) patients, even in high-risk cases, with favorable survival rates observed.
Article
Biophysics
Asmita Mishra, Joseph Pidala, Ram Thapa, Brian C. Betts, Hugo Fernandez, Frederick L. Locke, Taiga Nishihori, Lia Perez, Xuefeng Wang, Claudio Anasetti, Heather Jim
Summary: This prospective study on adult allogeneic hematopoietic cell transplantation recipients showed that the 6-minute walk test on day +30 post-transplant had the greatest impact on subsequent survival and non-relapse mortality. The findings suggest the importance of focusing on rehabilitation and physical activity for patient survival.
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Ephraim J. Fuchs, Shannon R. McCurdy, Scott R. Solomon, Tao Wang, Megan R. Herr, Dipenkumar Modi, Michael R. Grunwald, Taiga Nishihori, Michelle Kuxhausen, Stephanie Fingerson, Caroline McKallor, Asad Bashey, Yvette L. Kasamon, Yung-Tsi Bolon, Ayman Saad, Joseph McGuirk, Sophie Paczesny, Shahinaz M. Gadalla, Steven G. E. Marsh, Bronwen E. Shaw, Stephen R. Spellman, Stephanie J. Lee, Effie W. Petersdorf
Summary: HLA factors play an important role in the success of haploidentical transplantation. Disease-free survival is associated with matching status at individual HLA loci, with HLA-DRB1 and -DPB1 mismatches and HLA-C,-B leader, and -DQB1 matching being favorable. Considering HLA factors may help optimize the selection of haploidentical related donors.
Article
Hematology
Aleksandr Lazaryan, Stephanie Lee, Mukta Arora, Jongphil Kim, Brian Christopher Betts, Farhad Khimani, Taiga Nishihori, Nelli Bejanyan, Hien Liu, Mohamed A. Kharfan-Dabaja, Frederick L. Locke, Rebecca Gonzalez, Michael D. Jain, Marco L. Davila, Lia Elena Perez, Asmita Mishra, Ariel Perez Perez, Karlie Balke, Ernesto Ayala, Leonel Ochoa, Omar Castaneda Puglianini, Rawan Faramand, Melissa Alsina, Hany Elmariah, Michael L. Nieder, Hugo Fernandez, Claudio Anasetti, Joseph A. Pidala
Summary: The upfront therapy of chronic graft vs. host disease (cGVHD) with ofatumumab and prednisone demonstrated acceptable safety and potential efficacy. However, the response rates did not show significant superiority compared to the pre-specified benchmark.
Letter
Hematology
Ankit Kansagra, Angela Dispenzieri, Raphael Fraser, Noel Estrada-Merly, Surbhi Sidana, Taiga Nishihori, Doris K. Hansen, Larry D. Anderson, Rahul Banerjee, Naresh Bumma, Binod Dhakal, Jack Khouri, Heather Landau, Cindy Lee, Hira Mian, Sunita Nathan, Bipin Savani, Shaji Kumar, Muzaffar Qazilbash, Nina Shah, Anita D'Souza
Summary: POEMS syndrome, a paraneoplastic syndrome associated with a plasma cell neoplasm, requires effective treatment to control the underlying plasma cell clone. This study reports the outcomes of autoHCT in an international cohort of POEMS syndrome patients, emphasizing toxicities in comparison with multiple myeloma and long-term safety and outcomes.
Letter
Hematology
Ariel Perez, Grace Johnson, Kedar Patel, Brian Arciola, Anthony Wood, Christina A. Bachmeier, Julio C. Chavez, Bijal D. Shah, Farhad Khimani, Taiga Nishihori, Aleksandr Lazaryan, Marco L. Davila, Rahul Mhaskar, Frederick L. Locke, Sameh Gaballa, Michael D. Jain
Article
Hematology
Taiga Nishihori, James E. Hoffman, Anne Huff, Gurpreet S. Kapoor, Ioanna Eleftheriadou, Stefan Zajic, Alisa Urbano, Sunil Suchindran, Michael Chisamore, Jimson W. D'Souza, Thomas Faitg, Aaron P. Rapoport
Summary: This pilot study evaluated the safety and efficacy of letetresgene autoleucel (lete-cel) alone or in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma. The results showed transient antitumor activity and manageable safety profile of letetresgene autoleucel in these patients.
Article
Oncology
Laura B. Oswald, Lisa M. Gudenkauf, Xiaoyin Li, Gabriel De Avila, Lauren C. Peres, Kedar Kirtane, Brian D. Gonzalez, Aasha I. Hoogland, Oanh Nguyen, Yvelise Rodriguez, Rachid C. Baz, Kenneth H. Shain, Melissa Alsina, Frederick L. Locke, Ciara Freeman, Omar Castaneda Puglianini, Taiga Nishihori, Hien Liu, Brandon Blue, Ariel Grajales-Cruz, Heather S. L. Jim, Doris K. Hansen
Summary: This study aimed to evaluate patient-reported outcomes among patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel (ide-cel) therapy. The findings showed that most patients reported significant and meaningful improvements in health-related quality of life and physical well-being after CAR T treatment.
Article
Hematology
Hemant S. Murthy, Mei-Jie Zhang, Karen Chen, Sairah Ahmed, Uday Deotare, Siddhartha Ganguly, Ankit Kansagra, Fotios V. Michelis, Taiga Nishihori, Mrinal Patnaik, Muhammad Bilal Abid, Mahmoud Aljurf, Yasuyuki Arai, Ulrike Bacher, Talha Badar, Sherif M. Badawy, Karen Ballen, Minoo Battiwalla, Amer Beitinjaneh, Nelli Bejanyan, Vijaya Raj Bhatt, Valerie I. Brown, Rodrigo Martino, Jean-Yves Cahn, Paul Castillo, Jan Cerny, Saurabh Chhabra, Edward Copelan, Andrew Daly, Bhagirathbhai Dholaria, Miguel Angel Diaz Perez, Cesar O. Freytes, Michael R. Grunwald, Shahrukh Hashmi, Gerhard C. Hildebrandt, Omer Jamy, Jacinth Joseph, Christopher G. Kanakry, Nandita Khera, Maxwell M. Krem, Yachiyo Kuwatsuka, Hillard M. Lazarus, Lazaros J. Lekakis, Hongtao Liu, Dipenkumar Modi, Pashna N. Munshi, Alberto Mussetti, Neil Palmisiano, Sagar S. Patel, David A. Rizzieri, Sachiko Seo, Mithun Vinod Shah, Akshay Sharma, Melhm Sohl, Scott R. Solomon, Matthew Ulrickson, Celalettin Ustun, Marjolein van der Poel, Leo F. Verdonck, John L. Wagner, Trent Wang, Baldeep Wirk, Amer Zeidan, Mark Litzow, Partow Kebriaei, Christopher S. Hourigan, Daniel J. Weisdorf, Wael Saber, Mohamed A. Kharfan-Dabaja
Summary: This study analyzed the outcomes of allo-HCT in BPDCN patients and found that it provides durable remissions and long-term survival. Younger age and allo-HCT in CR1 were associated with improved survival, while the use of MAC-TBI reduced relapse risk and improved DFS. Further research and innovative strategies are needed to improve the outcomes of BPDCN.
Article
Biophysics
Ashley M. Nelson, Heather S. L. Jim, Brent J. Small, Taiga Nishihori, Brian D. Gonzalez, Julie M. Cessna, Kelly A. Hyland, Meredith E. Rumble, Paul B. Jacobsen
BONE MARROW TRANSPLANTATION
(2018)